Search

Your search keyword '"Prostatic Hyperplasia pathology"' showing total 4,659 results

Search Constraints

Start Over You searched for: Descriptor "Prostatic Hyperplasia pathology" Remove constraint Descriptor: "Prostatic Hyperplasia pathology"
4,659 results on '"Prostatic Hyperplasia pathology"'

Search Results

1. Combining untargeted and targeted metabolomics to reveal the mechanisms of herb pair Anemarrhena asphodeloides Bunge and Phellodendron chinense C. K. Schneid on benign prostatic hyperplasia.

2. Y-27632 targeting ROCK1&2 modulates cell growth, fibrosis and epithelial-mesenchymal transition in hyperplastic prostate by inhibiting β-catenin pathway.

3. Inflammation impacts androgen receptor signaling in basal prostate stem cells through interleukin 1 receptor antagonist.

4. [Benign prostatic hyperplasia].

5. Investigation on clinical risk factors of bladder lesion by machine learning based interpretable model.

6. Single-cell sequencing analysis revealed that NEAT1 was a potential biomarker and therapeutic target of prostate cancer.

7. A systematic review of robot-assisted simple prostatectomy outcomes by prostate volume.

8. Comparative transcriptome of normal and cancer-associated fibroblasts.

9. Establishing and Characterizing the Molecular Profiles, Cellular Features, and Clinical Utility of a Patient-Derived Xenograft Model Using Benign Prostatic Tissues.

10. Chrysin attenuates epithelial prostatic hyperplasia in the ventral prostate of spontaneously hypertensive rats.

11. Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, a mitochondrial protein essential for efficient function of the electron transport chain.

12. Effect of methanol extract of Plectranthus esculentus N.E.Br tuber and its fractions on indices of benign prostatic hyperplasia in Wistar rats.

13. Cell death and DNA damage via ROS mechanisms after applied antibiotics and antioxidants doses in prostate hyperplasia primary cell cultures.

14. [Study on the correlation between glycolipids and prostate volume in patients with benign prostatic hyperplasia].

15. Wenshenqianlie capsule improves benign prostatic hyperplasia via its anti-inflammatory and antioxidant effects.

16. A comparative study of histotripsy parameters for the treatment of fibrotic ex-vivo human benign prostatic hyperplasia tissue.

17. Comparative Analysis of Three Surgical Instruments in the Treatment of High Critical Enucleation of Prostate.

18. Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer.

19. Androgen receptor deficiency-induced TUG1 in suppressing ferroptosis to promote benign prostatic hyperplasia through the miR-188-3p/GPX4 signal pathway.

20. LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA.

22. Top-down holmium laser enucleation of the prostate (HoLEP) versus traditional HoLEP for the treatment of benign prostatic hyperplasia (BPH): 1-year outcomes of a randomized controlled trial.

24. Comparison of perioperative and short-terms outcomes of en-bloc Holmium laser enucleation of the prostate (HoLEP) and robot-assisted simple prostatectomy: a propensity-score matching analysis.

25. Prostate-specific antigen, androgen, progesterone and oestrogen receptors in Benign prostatic hyperplasia: human tissues and animal model study.

26. Microbiome analysis reveals the inducing effect of Pseudomonas on prostatic hyperplasia via activating NF-κB signalling.

27. Apoptosis-Cell Cycle-Autophagy Molecular Mechanisms Network in Heterogeneous Aggressive Phenotype Prostate Hyperplasia Primary Cell Cultures Have a Prognostic Role.

28. Does concordance between preoperatively measured prostate volume and enucleated weight predict outcomes in endoscopic enucleation of the prostate? Results from the REAP database.

29. Evaluation of the Efficacy and Safety of Bipolar and Monopolar Transurethral Prostate Resection in Geriatric Patients.

30. Effects of carvedilol on human prostate tissue contractility and stromal cell growth pointing to potential clinical implications.

31. New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction-ICI-RS 2023.

32. Di-(2-ethylhexyl) phthalate promotes benign prostatic hyperplasia through KIF11-Wnt/β-catenin signaling pathway.

33. The correlation between obesity and prostate volume in patients with benign prostatic hyperplasia: A prospective cohort study.

34. A Novel Liquid Biopsy Method Based on Specific Combinations of Vesicular Markers Allows Us to Discriminate Prostate Cancer from Hyperplasia.

35. Ageratum conyzoides Extract Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia via Inhibiting Proliferation, Inflammation of Prostates, and Induction of Apoptosis in Rats.

36. CCR2 + monocytes/macrophages drive steroid hormone imbalance-related prostatic fibrosis.

37. Intrinsic and extrinsic factors causing hyperplasia of the prostate.

38. Computerized metric assessment of glandular tissue volume within the peripheral zone of the prostate using combined magnetic resonance imaging and histopathology: Possible pathophysiological implications on prostate cancer development.

39. Enhanced prostatic Esr1 + luminal epithelial cells in the absence of SRD5A2.

40. Modulation of adipose-derived stem cell behavior by prostate pathology-associated plasma: insights from in vitro exposure.

41. Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer.

42. The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy.

43. Aging-Related Mitochondrial Dysfunction Is Associated With Fibrosis in Benign Prostatic Hyperplasia.

44. Clinical value of neutrophil to lymphocyte ratio and ultrasonic parameters in the diagnosis of bladder outlet obstruction in benign prostatic hyperplasia.

45. miR-1202 regulates BPH-1 cell proliferation, apoptosis, and epithelial-to-mesenchymal transition through targeting HMGCL.

46. Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese.

47. Activation of the cGMP/PKG/ERK signaling pathway associated with PDE5Is inhibits fibroblast activation by downregulating autophagy in early progressive benign prostatic hyperplasia.

48. The Effects of Caloric Restriction on Inflammatory Targets in the Prostates of Aged Rats.

49. Aberrant activation of TGF-β/ROCK1 enhances stemness during prostatic stromal hyperplasia.

50. Potential role of oxidative stress in pathogenesis of benign prostatic hyperplasia in male dogs.

Catalog

Books, media, physical & digital resources